Drug General Information (ID: DDI36KBY7D)
Drug Name			Dolasetron		Drug Info		Panobinostat		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiemetics				Histone Deacetylase Inhibitors
Structure

Mechanism of Dolasetron-Panobinostat Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Dolasetron				Panobinostat
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Dolasetron and Panobinostat

Recommended Action
Management		Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided. Anti-emetic drugs with known QT prolonging risk such as dolasetron, granisetron, ondansetron, palonosetron, and tropisetron may be used with frequent ECG monitoring. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting panobinostat therapy and periodically during treatment as clinically indicated.

References
1	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.